Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Metronomic Cyclophosphamide in Chest Wall Breast Cancer
NCT03971045Phase 2Recruiting
- Sponsor
- European Institute of Oncology
- Start
- May 2020
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in inflammatory breast cancer (IBC), sponsored by European Institute of Oncology. Started May 2020; status: recruiting.
02
Drugs
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT03971045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971045.